BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5-11 Years of Age: A Test Negative Design

Sara Y Tartof; Timothy B Frankland; Laura Puzniak; Jeff M Slezak; Vennis Hong; Harpreet Takhar; Oluwaseye A Ogun; Sarah Simmons; Fagen Xie; Joann Zamparo; Bradley K Ackerson; Luis Jodar; John M McLaughlin

doi:10.1093/jpids/piad005

BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5-11 Years of Age: A Test Negative Design

J Pediatric Infect Dis Soc. 2023 Apr 18;12(3):177-179. doi: 10.1093/jpids/piad005.

Authors

Affiliations

¹ Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, USA.
² Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.
³ Kaiser Permanente Hawaii Center for Integrated Health Care Research, Honolulu, Hawaii, USA.
⁴ Pfizer Inc., Collegeville, Pennsylvania, USA.
⁵ Southern California Permanente Medical Group, Harbor City, California, USA.

Abstract

In a 1:1 matched test-negative design among 5- to 11-year-olds in the Kaiser Permanente Southern California health system (n = 3984), BNT162b2 effectiveness against the omicron-related emergency department or urgent care encounters was 60% [95%CI: 47-69] <3 months post-dose-two and 28% [8-43] after ≥3 months. A booster improved protection to 77% [53-88].

Keywords: BNT162b2; COVID-19; Kaiser Permanente; SARS-CoV-2; United States; booster; delta; effectiveness; omicron; pediatric; real-world; test-negative.

MeSH terms

BNT162 Vaccine*
COVID-19*
Child
Emergency Service, Hospital
Humans

Substances

BNT162 Vaccine

Grants and funding

Pfizer